http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014171913-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2c2765df456458a18b534f9fe447e18a |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6056 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2730-10122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2730-10134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-292 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-02 |
| filingDate | 2013-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75db01a445fd56c4af0f8197ebde34e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfc9e2a487ff5f23f19dd02c87dc39f8 |
| publicationDate | 2014-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2014171913-A2 |
| titleOfInvention | Immunoglobulin fc fragment tagging activation of endogenous cd4 and cd8 t cells and enhancement of antitumor effects of lentivector immunization |
| abstract | A lentivector has been engineered to express a fusion antigen composed of hepatitis B surface protein (HBsAg) and lgG2a Fc fragment (HBS-Fc-lv) to increase both the magnitude of CD8 response and to induce effective co-activation of CD4 T cells. Immunization with this HBS-Fc-lv caused significant regression of established tumors. Immunological analysis revealed that, compared to HBS-lv without the Fc fragment, immunization with HBS-Fc-lv markedly increased the number of functional CD8 and CD4 T cells and the level of Th1/Tc1 -like cytokines in the tumor, while substantially decreasing the Treg ratio. The favorable immunologic changes in tumor lesions and the improvement of antitumor effects from HBS-Fc-lv immunization were dependent on the CD4 activation, which was Fc receptor mediated. Adoptive transfer of the CD4 T cells from the HBS-Fc-lv immunized mice could activate endogenous CD8 T cells in an IFNy-dependent manner. Endogenous CD4 T cells can be activated by lentivirus expressing Fc-tagged antigen to provide another layer of help, i.e. , creating a Th1/Tc1 like pro-inflammatory milieu within the tumor lesion to help the effector phase of immune responses to enhance the antitumor effect. |
| priorityDate | 2012-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 515.